Feel free to contact your local B. Braun sales representative or place orders via Customer Service at Please check with your wholesaler for all available inventory.
APP has the 10mL vials and mL vials on back-order with estimated releases mid-March, APP has the 50mL vials also on backorder with estimated release early-April, The mL vials have been discontinued. For more information visit: Spectrum Pharmaceuticals web site. Lundbeck expects Mustargen to be available again during Updates will be provided as they become available.
These instructions provide for an alternative oral suspension when commercially manufactured oral suspension formulation is not readily available. Please refer to the Tamiflu package insert for information regarding compounding an oral suspension from Tamiflu 75mg capsules or see the following link for healthcare professionals: Haloperidol Decanoate Injection updated Martes 10 de Mayo de If a pharmacy cannot obtain product from their wholesaler, please have the wholesaler contact Teva directly to place an emergency order.
Bedford Customer Service Manufacturing delaysBedford anticipates release of the mg and 1g presentations in late May. The mg presentation has been discontinued. Limited supplies continue to be available. Expect increased product availability in May Shire Customer Service Number: All other strengths market availability: Hospira anticipates releasing product sometime in APP is anticipating batch releases to resume in the first quarter of Teva Pharmaceuticals Manufacturing delays 15 unit vials NDC and 30 unit vials NDC are now available and the company is reviewing orders prior to shipping.
Bedford 15 unit vial NDC , 30 unit vial NDC Product discontinued Bedford currently has all presentations discontinued.
Due to increases in demand, American Regent, Inc. Contact your wholesaler regarding product availability. The 10 mL vials have been discontinued. Bedford Product discontinued Bedford currently has all presentations discontinued. Recall -- Firm Press Release regarding recall of certain lots that may contain particulate matter.
No information at this time regarding when the product will be available. The 2g presentation has been discontinued. APP has been able to increase production to help address the shortage and estimates additional supplies to be released by end of April. Bedford will release daunorubicin solution for injection, 20 mg and 50 mg, in the next 3-months. The firm has placed their product on hold with no estimated release date. APP is continuing to release the product as it becomes available.
Baxter is currently experiencing a back order situation on the 2 mL ampuls NDC Baxter has accelerated production and will have product available by the end of April. Baxter is experiencing a back order situation on all codes and estimates the following product availability: Product will be made available as it is released.
Emergency supplies of the ADD-Vantage vials are available for direct orders. Teva Pharmaceuticals Manufacturing delays Teva is releasing all strengths on allocation: Bedford Manufacturing delays Bedford anticipates release of the 50mg presentation in the next 3months and release of the 10 mg, 25 mg, and mg solutions in the next 6-months. The 25 mL and 50 mL vials are on back order. Manufacturing delays Hospira is working to resolve the manufacturng delay concerning the mL, package of 12 NDC and mL, package of 12 NDC and additional information on availability will be forthcoming.
West-Ward Pharmaceuticals Customer Service: Bedford Laboratories Customer Service Product discontinued Bedford has all presentations of the Haloperidol Decanoate discontinued. Hospira is working with FDA to address the issues that led to the shortage.
Baxter has the following Intralipid emulsions available through normal distribution: Teva Pharmaceuticals Manufacturing delays Teva has leucovorin calcium lyophilized powder mg and mg vials on back order and the company does not anticipate release until April APP Pharmaceuticals APP has recently launched their leucovorin injection in response to the ongoing shortage.
APP is currently back-ordered. There is potential for dosing errors when interchanging leucovorin and levoleucovorin Fusilev. The dose of levoleucovorin Fusilev is one-half the dose of racemic leucovorin injection e. Bedford Laboratories Customer Service: Bedford has all lorazepam injection presentations on long-term back order and the company cannot estimate a release date.
Expect sporadic backorders for the next couple of months. Mallinckrodt expects to have continued gradual improvement over the next two months, with full recovery by July The out of stock tablets are expected to be on intermittent backorder until approximately May Lots are currently being manufactured and will be release for distribution as product becomes available.
There is not yet an availability date for the mg capsules. Product is in adequate supply. Lundbeck voluntarily recalled NeoProfen as a safety precaution. As NeoProfen stock is being replenished by the manufacturer, supply is anticipated to be available in mid UCB is committed to bringing Neupro to U.
Additional lots are scheduled for manufacturing and will be available for distribution in the June — July timeframe. Sandoz anticipates increased product availability by the end of May. American Regent Customer Service: Hospira understands the critical necessity of this molecule to the healthcare community and is quickly assessing manufacturing re-start timing and anticipated market recovery dates.
At this time an ETA is unavailable. The company has their 20 mL and 50 mL presentations on intermittent back order due to increased demand and the mL vials are on back order due to the prioritization of the 20mL and 50mL. We expect to be shipping the mL vials to customers in May. All product is being shipped to sole contracted customers at this time.
The planned date of release will be posted once available. Guardian Labs cannot estimate when product will be available. The mL vials are on back order and the company estimates a release date of early-April, Limited emergency supplies are available from Teva. Product support and fulfillment: Tamiflu 75mg, 45 mg and 30 mg capsules remain available. For those patients who have difficulty swallowing capsules, the contents can be mixed into sweetened liquids, such as chocolate syrup, as directed by a healthcare professional.
FDA approved levothyroxine products continue to be available from multiple manufacturers. Sun Pharmaceutical Industries, Inc. Caraco Pharmaceutical Labs, Ltd. All product strengths other than 25 mg are currently available on an allocated basis. Please see the following link for updated information: APP is currently back-ordered on all presentations of Bleomycin for Injection at this time.
APP has all calcium gluconate products on intermittent back-order, due to increased demand, and the company has regular releases and distributes inventory directly to the wholesale channel. APP is continuing to allocate as releases occur: Teva has daunorubicin solution for injection on back order and estimates a release date of August, Bedford will release 20 mg lyophilized powder for injection in early May.
Teva is releasing all strengths on allocation: Bedford anticipates release of the 50mg presentation in the next 3months and release of the 10 mg, 25 mg, and mg solutions in the next 6-months.
Hospira has the following Liposyn III emulsion soybean oil products on backorder. Teva has leucovorin calcium lyophilized powder mg and mg vials on back order and the company does not anticipate release until April APP has recently launched their leucovorin injection in response to the ongoing shortage.